Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis

Company Overview

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Key Stats

• Today's Range: $5.03 to $5.16
• 50-Day Range: $5.01 to $7.02
• 52-Week Range: $3.96 to $10.07
• Volume: 38,380 shs
• Average Volume: 108,870 shs
• Market Capitalization: $140.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.67
• Consensus Rating: Buy

Fennec Pharmaceuticals Stock Analysis - MarketRank™

Fennec Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat, and ranked 675th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fennec Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fennec Pharmaceuticals are expected to decrease in the coming year, from ($0.11) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fennec Pharmaceuticals is -50.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fennec Pharmaceuticals is -50.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.49% of the float of Fennec Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 18.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Fennec Pharmaceuticals has recently increased by 4.17%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fennec Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Fennec Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.49% of the float of Fennec Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 18.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Fennec Pharmaceuticals has recently increased by 4.17%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $195,089.00 in company stock.

Percentage Held by Insiders

10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FENC Stock Analysis - Frequently Asked Questions

How have FENC shares performed this year?

Fennec Pharmaceuticals' stock was trading at $6.32 at the beginning of 2025. Since then, FENC stock has decreased by 19.6% and is now trading at $5.08.
View the best growth stocks for 2025 here.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.08. The company earned $6.97 million during the quarter, compared to analyst estimates of $9.13 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative trailing twelve-month return on equity of 53.38%.
Read the conference call transcript.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 4/19/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FENC
• CIK: 1211583
• Web: www.fennecpharma.com
• Phone: 919-636-4530
• Fax: 919-890-0490
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.67
• High Stock Price Target: $15.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +169.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,050,000.00
• Net Margins: -2.30%
• Pretax Margin: -2.31%
• Return on Equity: -53.38%
• Return on Assets: -2.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.80
• Quick Ratio: 7.64

Sales & Book Value

• Annual Sales: $47.54 million
• Price / Sales: 2.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.43) per share
• Price / Book: -11.81

Miscellaneous

• Outstanding Shares: 27,594,000
• Free Float: 24,536,000
• Market Cap: $140.18 million
• Optionable: Optionable
• Beta: 0.32